Suzhou 4a Biotech Co., Ltd.  has recently completed a Pre-A round of financing of tens of millions (CNY). This round of financing is exclusively invested by Yuanshan Investment, a subsidiary of Yichuang Investment. The raised funds will be used in Suzhou 4a Biotech builds a high-end international antibody platform featuring flow cytometry technology. At the same time, the company plans to officially open Series A financing in the near future.

Suzhou 4a Biotech, the predecessor of Beijing 4a Biotech, was established in 2009. It has an antibody R&D and production platform represented by flow antibody with complete independent intellectual property rights, and occupies a leading position in the Chinese industry. Flow technology is widely used in basic research in life sciences, clinical diagnosis of various types of diseases, immune monitoring, cell therapy and other fields. The flow track has huge growth potential and market space both in China and other countries. Through this financing, Suzhou 4a Biotech will further consolidate the advantages of flow reagents, expand upstream, mid-stream and downstream cooperation, carry out international marketing, and strive to build a commercial antibody platform with richer connotations and international standards.

After this round of financing, the company's core management team has been further strengthened. The company's chief operating officer, Mr. Zhao Kan, will serve as the company's general manager. Senior experts with ten years of experience in diagnostic product development hold key positions such as the head of the company's strategic research center and the head of the technology transformation center. In addition, Suzhou 4a Biotech will also gather several high-end talents from well-known biopharmaceutical enterprises all over the world to participate in the company's internationalization strategy.